Status:
COMPLETED
Observational Study Describing the Usual Clinical Practice Use of NovoSeven® in the Home Treatment of Joint Bleeds in Patients With Haemophilia A or B and Inhibitors
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Congenital Bleeding Disorder
Haemophilia A
Eligibility:
MALE
2+ years
Brief Summary
This trial is conducted in Africa and Asia. The aim of this study is to evaluate the efficacy of home treatment of joint bleeds (haemarthrosis) with NovoSeven® (activated recombinant human factor VII)...
Eligibility Criteria
Inclusion
- Patients with congenital haemophilia and inhibitors to factor VIII or IX
- Indication of activated recombinant human factor VII for the treatment of joint bleeding located in elbow, shoulder, wrist, hip, knee, ankle
Exclusion
- Known or suspected allergy to study product(s) or related products
- Clinically relevant coagulation disorders other than congenital haemophilia A or B
Key Trial Info
Start Date :
October 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2012
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT01234545
Start Date
October 1 2010
End Date
April 1 2012
Last Update
November 14 2014
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Algiers, Algeria, 16035
2
Casablanca, Morocco, 20000
3
Muscat, Oman
4
Riyadh, Saudi Arabia, 3542